Results of the first phase 1 clinical trial of the HER‐2/<i>neu</i> peptide (GP2) vaccine in disease‐free breast cancer patients

Abstract

The GP2 peptide vaccine appears safe and well tolerated with minimal local/systemic toxicity. GP2 elicited HER-2/neu-specific immune responses, including epitope spreading, in high-risk, lymph node-negative breast cancer patients. These findings support further investigation of the GP2 vaccine for the prevention of breast cancer recurrence.